The Multiple Biological Functions of Dipeptidyl Peptidase-4 in Bone Metabolism

Overview

Journal Front Endocrinol (Lausanne)

Specialty Endocrinology

Date 2022 May 19

PMID 35586625

Authors

Qiu Yang

Bing Fu

Dan Luo

Haibo Wang

Hongyi Cao

Xiang Chen

Li Tian

XiJie Yu

Affiliations

Soon will be listed here.

Abstract

Dipeptidyl peptidase-4 (DPP4) is a ubiquitously occurring protease involved in various physiological and pathological processes ranging from glucose homeostasis, immunoregulation, inflammation to tumorigenesis. Recently, the benefits of DPP4 inhibitors as novel hypoglycemic agents on bone metabolism have attracted extensive attraction in many studies, indicating that DPP4 inhibitors may regulate bone homeostasis. The effects of DPP4 on bone metabolism are still unclear. This paper thoroughly reviews the potential mechanisms of DPP4 for interaction with adipokines, bone cells, bone immune cells, and cytokines in skeleton system. This literature review shows that the increased DPP4 activity may indirectly promote bone resorption and inhibit bone formation, increasing the risk of osteoporosis. Thus, bone metabolic balance can be improved by decreasing DPP4 activities. The substantial evidence collected and analyzed in this review supports this implication.

Citing Articles

Insights into the Roles of GLP-1, DPP-4, and SGLT2 at the Crossroads of Cardiovascular, Renal, and Metabolic Pathophysiology.

Gaggini M, Sabatino L, Suman A, Chatzianagnostou K, Vassalle C Cells. 2025; 14(5).

PMID: 40072115 PMC: 11898734. DOI: 10.3390/cells14050387.

New Insights into the Pleiotropic Actions of Dipeptidyl Peptidase-4 Inhibitors Beyond Glycaemic Control.

Mangoura S, Ahmed M, Zaka A touchREV Endocrinol. 2024; 20(2):19-29.

PMID: 39526061 PMC: 11548370. DOI: 10.17925/EE.2024.20.2.5.

Commentary on "Structural characterization of SLYM - a 4th meningeal membrane".

Siegenthaler J, Betsholtz C Fluids Barriers CNS. 2024; 21(1):69.

PMID: 39252039 PMC: 11385822. DOI: 10.1186/s12987-024-00568-y.

Function and Regulation of Bone Marrow Adipose Tissue in Health and Disease: State of the Field and Clinical Considerations.

Zhang X, Tian L, Majumdar A, Scheller E Compr Physiol. 2024; 14(3):5521-5579.

PMID: 39109972 PMC: 11725182. DOI: 10.1002/cphy.c230016.

The multiple actions of dipeptidyl peptidase 4 (DPP-4) and its pharmacological inhibition on bone metabolism: a review.

Pechmann L, Pinheiro F, Andrade V, Moreira C Diabetol Metab Syndr. 2024; 16(1):175.

PMID: 39054499 PMC: 11270814. DOI: 10.1186/s13098-024-01412-x.

References

Wronkowitz N, Gorgens S, Romacho T, Villalobos L, Sanchez-Ferrer C, Peiro C . Soluble DPP4 induces inflammation and proliferation of human smooth muscle cells via protease-activated receptor 2. Biochim Biophys Acta. 2014; 1842(9):1613-21. DOI: 10.1016/j.bbadis.2014.06.004. View

Mohan S, Hu Y, Edderkaoui B . Chemokine receptor 3 is a negative regulator of trabecular bone mass in female mice. J Cell Biochem. 2019; 120(8):13974-13984. DOI: 10.1002/jcb.28672. View

Mieczkowska A, Mansur S, Bouvard B, Flatt P, Thorens B, Irwin N . Double incretin receptor knock-out (DIRKO) mice present with alterations of trabecular and cortical micromorphology and bone strength. Osteoporos Int. 2014; 26(1):209-18. DOI: 10.1007/s00198-014-2845-8. View

Haderslev K, Jeppesen P, Hartmann B, Thulesen J, Sorensen H, Graff J . Short-term administration of glucagon-like peptide-2. Effects on bone mineral density and markers of bone turnover in short-bowel patients with no colon. Scand J Gastroenterol. 2002; 37(4):392-8. DOI: 10.1080/003655202317316006. View

Wintges K, Beil F, Albers J, Jeschke A, Schweizer M, Claass B . Impaired bone formation and increased osteoclastogenesis in mice lacking chemokine (C-C motif) ligand 5 (Ccl5). J Bone Miner Res. 2013; 28(10):2070-80. DOI: 10.1002/jbmr.1937. View

Carbone L, Buzkova P, Fink H, Robbins J, Bethel M, Isales C . Association of DPP-4 activity with BMD, body composition, and incident hip fracture: the Cardiovascular Health Study. Osteoporos Int. 2017; 28(5):1631-1640. PMC: 5653373. DOI: 10.1007/s00198-017-3916-4. View

Henriksen D, Alexandersen P, Hartmann B, Adrian C, Byrjalsen I, Bone H . Four-month treatment with GLP-2 significantly increases hip BMD: a randomized, placebo-controlled, dose-ranging study in postmenopausal women with low BMD. Bone. 2009; 45(5):833-42. DOI: 10.1016/j.bone.2009.07.008. View

Zhang Q, Chen B, Yan F, Guo J, Zhu X, Ma S . Interleukin-10 inhibits bone resorption: a potential therapeutic strategy in periodontitis and other bone loss diseases. Biomed Res Int. 2014; 2014:284836. PMC: 3947664. DOI: 10.1155/2014/284836. View

Lubberts E, Koenders M, van den Berg W . The role of T-cell interleukin-17 in conducting destructive arthritis: lessons from animal models. Arthritis Res Ther. 2005; 7(1):29-37. PMC: 1064899. DOI: 10.1186/ar1478. View

10.

Zhuge F, Ni Y, Nagashimada M, Nagata N, Xu L, Mukaida N . DPP-4 Inhibition by Linagliptin Attenuates Obesity-Related Inflammation and Insulin Resistance by Regulating M1/M2 Macrophage Polarization. Diabetes. 2016; 65(10):2966-79. DOI: 10.2337/db16-0317. View

11.

Khor E, Wee N, Baldock P . Influence of hormonal appetite and energy regulators on bone. Curr Osteoporos Rep. 2013; 11(3):194-202. DOI: 10.1007/s11914-013-0157-0. View

12.

Ikushima H, Munakata Y, Ishii T, Iwata S, Terashima M, Tanaka H . Internalization of CD26 by mannose 6-phosphate/insulin-like growth factor II receptor contributes to T cell activation. Proc Natl Acad Sci U S A. 2000; 97(15):8439-44. PMC: 26966. DOI: 10.1073/pnas.97.15.8439. View

13.

Janssen P, Rotondo A, Mule F, Tack J . Review article: a comparison of glucagon-like peptides 1 and 2. Aliment Pharmacol Ther. 2012; 37(1):18-36. DOI: 10.1111/apt.12092. View

14.

Feng Y, Su L, Zhong X, Guohong W, Xiao H, Li Y . Exendin-4 promotes proliferation and differentiation of MC3T3-E1 osteoblasts by MAPKs activation. J Mol Endocrinol. 2015; 56(3):189-99. DOI: 10.1530/JME-15-0264. View

15.

Martinez-Navio J, Casanova V, Pacheco R, Naval-Macabuhay I, Climent N, Garcia F . Adenosine deaminase potentiates the generation of effector, memory, and regulatory CD4+ T cells. J Leukoc Biol. 2010; 89(1):127-36. DOI: 10.1189/jlb.1009696. View

16.

Lee G . The Balance of Th17 versus Treg Cells in Autoimmunity. Int J Mol Sci. 2018; 19(3). PMC: 5877591. DOI: 10.3390/ijms19030730. View

17.

Adamopoulos I, Chao C, Geissler R, LaFace D, Blumenschein W, Iwakura Y . Interleukin-17A upregulates receptor activator of NF-kappaB on osteoclast precursors. Arthritis Res Ther. 2010; 12(1):R29. PMC: 2875663. DOI: 10.1186/ar2936. View

18.

Rohrborn D, Eckel J, Sell H . Shedding of dipeptidyl peptidase 4 is mediated by metalloproteases and up-regulated by hypoxia in human adipocytes and smooth muscle cells. FEBS Lett. 2014; 588(21):3870-7. DOI: 10.1016/j.febslet.2014.08.029. View

19.

Zhong Q, Itokawa T, Sridhar S, Ding K, Xie D, Kang B . Effects of glucose-dependent insulinotropic peptide on osteoclast function. Am J Physiol Endocrinol Metab. 2006; 292(2):E543-8. DOI: 10.1152/ajpendo.00364.2006. View

20.

Kiesel J, Buchwald Z, Aurora R . Cross-presentation by osteoclasts induces FoxP3 in CD8+ T cells. J Immunol. 2009; 182(9):5477-87. DOI: 10.4049/jimmunol.0803897. View